

Investigator Curriculum Vitae

This template may be used by Sponsors of clinical trials as part of the application dossier.

A separate document should be completed and submitted for each site.

This template has been developed and endorsed by the EU Clinical Trials Expert Group to comply with Regulation (EU) No. 536/2014 Clinical Trials on Medicinal Products for Human Use.

Personal Information

Name:	Claudia Codipietro
Title:	MD
Profession:	MD, Oncology resident
Current position:	Medical oncology resident

Professional Registrationⁱ

Registration number:	00000-11019
Registration body:	Albo dei Medici Chirurghi della Provincia di CAGLIARI
Registration expiry date (if applicable):	NA
Registration state/province (if applicable):	Italy

Education and Qualificationsⁱⁱ

Institution name	Qualification	Year
Università degli studi di Cagliari	Post graduate student in medical Oncology (resident)	Ongoing
Università degli studi di Cagliari	Medical Degree, cum laude	2021

Investigator Curriculum Vitae

Current employment

Institution name: Azienda Ospedaliero-Universitaria di Cagliari – P.O. Duilio Casula - Policlinico di Monserrato - Università degli studi di Cagliari

Department: SC Oncologia Medica

Institution address: S.S. 554 KM 4, 500 Bivio per Sestu - 09042 Monserrato (CA)

Telephone number:

E-mail address:

Professional experienceⁱⁱⁱ

Position	Institution name and department	Start Year	End year
Post graduate student in medical Oncology (resident)	Azienda Ospedaliero-Universitaria di Cagliari – P.O. Duilio Casula - Policlinico di Monserrato - Università degli studi di Cagliari	2021	Ongoing
Medical guard	ASL 8 Cagliari	2021	Ongoing

Relevant clinical trial/study experience^{iv}

Investigator role	Therapeutic area	Type of trial	Year started	Phase	Ongoing
Sub Investigator	Colorectal cancer	Interventional trial	2024	III	Yes
Sub Investigator	Biliary tract cancer	Interventional trial	2024	III	Yes
Sub Investigator	Colorectal cancer	Interventional trial	2024	II	Yes
Sub Investigator	Breast Cancer	Interventional trial	2025	III	Yes
Sub Investigator	Gastroesophageal Cancer	Other research study	2025	Other	Yes

Investigator Curriculum Vitae

- Pubblicazioni in estenso su riviste scientifiche internazionali:

1. Ziranu, P., Pretta, A., Aimola, V., Cau, F., Mariani, S., D'Agata, A.P., Codipietro, C., Rizzo, D., Dell'Utri, V., Sanna, G., Moleda, G., Cadoni, A., Lai, E., Puzzone, M., Pusceddu, V., Castagnola, M., Scartozzi, M., and Faa, G. CD44: A New Prognostic Marker in Colorectal Cancer? *Cancers (Basel)*. 2024 Apr 19;16(8):1569.

- Poster congressi internazionali:

1. Platelet to lymphocyte ratio and platelet count: new frontiers as prognostic factors in metastatic colorectal cancer patients receiving anti-angiogenic drugs. Lai, E., Loi, F., Palmas, E., Codipietro, C., Pretta, A., Spanu, D., Mariani, S., D'Agata, A.P., Ziranu, P., Pusceddu, V., Puzzone, M., Cucca, M., Cadoni, C., Ledda, M.L., Semonella, F., Dell'Utri, V., Pozzari, M., Rizzo, D., Deias, G., Papalexis, G., Sanna, G., Moleda, G., Congiu, B., Bardanzellu, F., Contu, F., Piseddu, E., Cimbri, E., Maccioni, M., Aresu, E., Murgia, S., Pannella, G., Donisi, C., Astara, G., Massa, E., Madeddu, C., Scartozzi, M. AACR Annual Meeting 2025, Chicago, Illinois, USA, 25-30 April 2025. *Cancer Res (2025)* 85 (8_Supplement_1): 4653. Abstract and poster 4653. <https://doi.org/10.1158/1538-7445.AM2025-4653>
2. Prognostic factors for anti-angiogenic treatment in patients with metastatic colorectal cancer: New insights for an old issue from a single institution experience. Lai, E., Ziranu, P., Mariani, S., Loi, F., Palmas, E., D'Agata, A.P., Dell'Utri, V., Deias, G., Balconi, F., Rizzo, D., Papalexis, G., Codipietro, C., Sanna, G., Moleda, G., Donisi, C., Spanu, D., Pretta, A., Pusceddu, V., Puzzone, M., Scartozzi, M. 2024 ASCO Gastrointestinal Cancers Symposium, San Francisco, California, USA, 18-20 Jan 2024. Poster bd M14, abstract 206. *J Clin Oncol* 42, 2024 (suppl 3; abstr 206)
3. Comparison between different therapeutic sequences in patients affected by metastatic pancreatic ductal adenocarcinoma. Pretta, A., Giampieri, R., Nichetti, F., Ziranu, P., Lupi, A., Moleda, G., Andena, P., Felicetti, C., D'Agata, A.P., Pircher, C.C., Codipietro, C., Rota, S., Rizzo, D., Sanna, G., Lai, E., Puzzone, M., Pusceddu, V., Berardi, R., Niger, M., Scartozzi, M. 2024 ASCO Gastrointestinal Cancers Symposium, San Francisco, California, USA, 18-20 Jan 2024, *J Clin Oncol* 42, 2024 (suppl 3; abstr 674)
4. Immunonutrition supplementation for resectable gastric cancer during standard perioperative chemotherapy (CT) FLOT: A pivotal study, I-SUPPLY. Pusceddu, V., Donisi, C., Loi, F., Pretta, A., Mariani, S., Ziranu, P., Puzzone, M., Lai, E., Pozzari, M., Cimbri, E., Maccioni, A., Rizzo, D., Codipietro, C., Dell'Utri, V., D'Agata, A.P., Cadeddu, M., and Scartozzi, M. 2023 ASCO Breakthrough, 3-5 August 2023, Yokohama, Japan, *JCO Global Oncology* 9, 2023 (suppl 1; abstr 57)

- Poster congressi Nazionali

5. Predictors of survival outcome in patients with refractory metastatic colorectal cancer in treatment with trifluridine/tipiracil. Palmas, E., Ziranu, P., Pretta, A., Deias, G., Loi, F., Codipietro, C., Dell'Utri, V., Rizzo, D., D'Agata, A.P., Cadeddu, M., Balconi, F., Saba, G., Donisi, C., Semonella, F., Parrino, A., Sanna, G., Puzzone, M., Pusceddu, V., Lai, E., Scartozzi, M. XXV Congresso Nazionale AIOM, Nov 10- 12, 2023, Rome, *Tumori Journal*, vol. 109, no. 2S, 2023, PAPERID-C39, pp. 108-109.
6. Influence of levothyroxine concomitant treatment on treatment responses and outcomes in patients with metastatic colorectal adenocarcinoma. Donisi, C., Pretta, A., Ziranu, P., Cimbri, E., Pinna, G., Palmas, E., Loi, F., Deias, G., Dell'Utri, V., Rizzo, D., D'Agata, A.P., Codipietro, C., Cadeddu, M., Balconi, F., Murgia, S., Mariani, S., Puzzone, M., Pusceddu, V., Lai, E., Scartozzi, M. XXV Congresso Nazionale AIOM, Nov 10-12, 2023, Rome, *Tumori Journal*, vol. 109, no. 2S, 2023, PAPERID-C70, pp. 128.

- Abstract congressi Nazionali

1. Looking for prognostic factors for anti-angiogenic treatment in metastatic colorectal cancer patients: a single centre experience. Lai, E., Ziranu, P., Palmas, E., Loi, F., Deias, G., Dell'Utri, V., Rizzo, D., Papalexis, G., D'Agata, A.P., Cadeddu, M., Codipietro, C., Spanu, D., Donisi, C., Balconi, F., Cimbri, E., Mariani, S., Pusceddu, V., Puzzone, M., Pretta, A., Scartozzi, M. XXV Congresso Nazionale AIOM, Nov 10-12, 2023, Rome, *Tumori Journal*, vol. 109, no. 2S, 2023, PAPERID-C81, pp. 135.

Investigator Curriculum Vitae

<u>Training</u>		
Research training (including GCP)	Institution name	Year obtained
Good Clinical Practice v.R3	TransCelerate Biopharma	2025
Good Clinical Practice v 2.1	TransCelerate Biopharma Inc	2024
IATA Training	Mayo Clinical Laboratories	2024

Date completed^v: 07/11/2025

ⁱ As per national legislation

ⁱⁱ Relevant to be an investigator

ⁱⁱⁱ This should cover the preceding 10 years as a maximum

^{iv} Idem

^v The CTR does not require signing individual documents in the clinical trial application – a request for signature could however be subject to national legislation.